DuChemBio

듀켐바이오 · 176750

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$131.7M (₩181.8B)

Overview

DuChemBio makes radiopharmaceuticals, specialist drugs that carry radioactive isotopes to diseased tissue in the body, where the radiation either lights up a tumour on a PET-CT scanner or destroys cancer cells directly.

Hospitals and nuclear-medicine departments are the primary users of these prescription-only drugs, which target cancer and brain diseases. Listed on KOSDAQ, Korea's tech and small-cap board, the company holds the broadest portfolio of PET-CT radiopharmaceuticals in Korea and operates over a dozen manufacturing sites, several of which carry pharmaceutical good-manufacturing-practice certification.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$28M

▲ +8.4% YoY

Operating profit · FY2025

US$5.4M

▲ +46.6% YoY

Net income · FY2025

US$4.7M

▼ −18.9% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2024	FY2025
Revenue	US$25.8M(₩35.6B)	US$28M(₩38.6B)
Operating profit	US$3.7M(₩5.1B)	US$5.4M(₩7.4B)
Net income	US$5.8M(₩8B)	US$4.7M(₩6.5B)

Revenue

FY2024US$25.8M
FY2025US$28M

Operating profit

FY2024US$3.7M
FY2025US$5.4M

Net income

FY2024US$5.8M
FY2025US$4.7M

Key ratios (FY2025)

ROE

13.2%

Debt/Eq

57.8%

Op. margin

19.3%

Net margin

16.8%

Rev. YoY

▲ +8.4%

Why it matters

DuChemBio completed a full acquisition of radiopharmaceutical R&D specialist ㈜라디오디앤에스랩스, founded by a nuclear-medicine professor at Seoul Asan Hospital, and plans to transfer its R&D activities to that subsidiary.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?